182 related articles for article (PubMed ID: 24510381)
1. Primary tumor resection as a component of multimodality treatment may improve local control and survival in patients with stage IV inflammatory breast cancer.
Akay CL; Ueno NT; Chisholm GB; Hortobagyi GN; Woodward WA; Alvarez RH; Bedrosian I; Kuerer HM; Hunt KK; Huo L; Babiera GV
Cancer; 2014 May; 120(9):1319-28. PubMed ID: 24510381
[TBL] [Abstract][Full Text] [Related]
2. Primary chemo-radiotherapy in the treatment of locally advanced and inflammatory breast cancer.
Bates T; Williams NJ; Bendall S; Bassett EE; Coltart RS
Breast; 2012 Jun; 21(3):330-5. PubMed ID: 22410111
[TBL] [Abstract][Full Text] [Related]
3. Once-daily radiation therapy for inflammatory breast cancer.
Brown L; Harmsen W; Blanchard M; Goetz M; Jakub J; Mutter R; Petersen I; Rooney J; Stauder M; Yan E; Laack N
Int J Radiat Oncol Biol Phys; 2014 Aug; 89(5):997-1003. PubMed ID: 24721591
[TBL] [Abstract][Full Text] [Related]
4. Impact of Locoregional Treatment on Prognosis of de novo Stage IV Breast Cancer: A Retrospective Long-Term Study of Chinese Population.
Wang W; Liu J; Wang J; Gao J; Wang X; Wang X
Gynecol Obstet Invest; 2019; 84(3):248-258. PubMed ID: 30448829
[TBL] [Abstract][Full Text] [Related]
5. Management of inflammatory breast cancer after neoadjuvant chemotherapy.
Abrous-Anane S; Savignoni A; Daveau C; Pierga JY; Gautier C; Reyal F; Dendale R; Campana F; Kirova YM; Fourquet A; Bollet MA
Int J Radiat Oncol Biol Phys; 2011 Mar; 79(4):1055-63. PubMed ID: 20478662
[TBL] [Abstract][Full Text] [Related]
6. Clinical Response to Induction Chemotherapy Predicts Outcome after Combined-Modality Therapy in Inflammatory Breast Cancer.
Loi M; Dunant A; Ghith S; Cascales-Garcia AM; Mazouni C; Pistilli B; Mathieu MC; Deutsch E; Arriagada R; Rivera S
Cancer Invest; 2019; 37(1):29-38. PubMed ID: 30656969
[TBL] [Abstract][Full Text] [Related]
7. Pathologic complete response and overall survival in breast cancer subtypes in stage III inflammatory breast cancer.
van Uden DJP; van Maaren MC; Bult P; Strobbe LJA; van der Hoeven JJM; Blanken-Peeters CFJM; Siesling S; de Wilt JHW
Breast Cancer Res Treat; 2019 Jul; 176(1):217-226. PubMed ID: 30972613
[TBL] [Abstract][Full Text] [Related]
8. Better survival after surgery of the primary tumor in stage IV inflammatory breast cancer.
van Uden DJP; van Maaren MC; Strobbe LJA; Bult P; Stam MR; van der Hoeven JJ; Siesling S; de Wilt JHW; Blanken-Peeters CFJM
Surg Oncol; 2020 Jun; 33():43-50. PubMed ID: 32561098
[TBL] [Abstract][Full Text] [Related]
9. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial.
Gianni L; Pienkowski T; Im YH; Tseng LM; Liu MC; Lluch A; Starosławska E; de la Haba-Rodriguez J; Im SA; Pedrini JL; Poirier B; Morandi P; Semiglazov V; Srimuninnimit V; Bianchi GV; Magazzù D; McNally V; Douthwaite H; Ross G; Valagussa P
Lancet Oncol; 2016 Jun; 17(6):791-800. PubMed ID: 27179402
[TBL] [Abstract][Full Text] [Related]
10. Factors associated with improved outcomes for metastatic inflammatory breast cancer patients.
Weiss A; Menen RS; Lin HY; Shen Y; Rosso KJ; Shaitelman S; Woodward W; Valero V; Ueno NT; Bedrosian I; Babiera G
Breast Cancer Res Treat; 2018 Jun; 169(3):615-623. PubMed ID: 29460033
[TBL] [Abstract][Full Text] [Related]
11. Should breast surgery be considered for patients with de novo metastatic inflammatory breast cancer?
Drapalik LM; Shenk R; Rock L; Simpson A; Amin AL; Miller ME
Am J Surg; 2024 Jul; 233():52-60. PubMed ID: 38458830
[TBL] [Abstract][Full Text] [Related]
12. Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin (NOAH) study.
Semiglazov V; Eiermann W; Zambetti M; Manikhas A; Bozhok A; Lluch A; Tjulandin S; Sabadell MD; Caballero A; Valagussa P; Baselga J; Gianni L
Eur J Surg Oncol; 2011 Oct; 37(10):856-63. PubMed ID: 21843921
[TBL] [Abstract][Full Text] [Related]
13. Extent of axillary surgery in inflammatory breast cancer: a survival analysis of 3500 patients.
Fayanju OM; Ren Y; Greenup RA; Plichta JK; Rosenberger LH; Force J; Suneja G; Devi GR; King TA; Nakhlis F; Hyslop T; Hwang ES
Breast Cancer Res Treat; 2020 Feb; 180(1):207-217. PubMed ID: 31960171
[TBL] [Abstract][Full Text] [Related]
14. Long-term survival after high-dose chemotherapy followed by peripheral stem cell rescue for high-risk, locally advanced/inflammatory, and metastatic breast cancer.
VanderWalde A; Ye W; Frankel P; Asuncion D; Leong L; Luu T; Morgan R; Twardowski P; Koczywas M; Pezner R; Paz IB; Margolin K; Wong J; Doroshow JH; Forman S; Shibata S; Somlo G
Biol Blood Marrow Transplant; 2012 Aug; 18(8):1273-80. PubMed ID: 22306735
[TBL] [Abstract][Full Text] [Related]
15. Exclusive alternating chemotherapy and radiotherapy in nonmetastatic inflammatory breast cancer: 20 years of follow-up.
Bourgier C; Pessoa EL; Dunant A; Heymann S; Spielmann M; Uzan C; Mathieu MC; Arriagada R; Marsiglia H
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):690-5. PubMed ID: 21277101
[TBL] [Abstract][Full Text] [Related]
16. Inflammatory breast cancer: a single centre analysis.
Gogia A; Raina V; Deo SV; Shukla NK; Mohanti BK; Sharma DN
Asian Pac J Cancer Prev; 2014; 15(7):3207-10. PubMed ID: 24815472
[TBL] [Abstract][Full Text] [Related]
17. The Impact of Residual Disease After Preoperative Systemic Therapy on Clinical Outcomes in Patients with Inflammatory Breast Cancer.
Nakhlis F; Regan MM; Warren LE; Bellon JR; Hirshfield-Bartek J; Duggan MM; Dominici LS; Golshan M; Jacene HA; Yeh ED; Mullaney EE; Overmoyer B
Ann Surg Oncol; 2017 Sep; 24(9):2563-2569. PubMed ID: 28560598
[TBL] [Abstract][Full Text] [Related]
18. Comparison of survival in non-metastatic inflammatory and other T4 breast cancers: a SEER population-based analysis.
Jiao D; Zhang J; Zhu J; Guo X; Yang Y; Xiao H; Liu Z
BMC Cancer; 2021 Feb; 21(1):138. PubMed ID: 33549037
[TBL] [Abstract][Full Text] [Related]
19. Inflammatory Breast Cancer: Patterns of Failure and the Case for Aggressive Locoregional Management.
Warren LE; Guo H; Regan MM; Nakhlis F; Yeh ED; Jacene HA; Hirshfield-Bartek J; Overmoyer BA; Bellon JR
Ann Surg Oncol; 2015 Aug; 22(8):2483-91. PubMed ID: 25791789
[TBL] [Abstract][Full Text] [Related]
20. Circulating tumor cells in newly diagnosed inflammatory breast cancer.
Mego M; Giordano A; De Giorgi U; Masuda H; Hsu L; Giuliano M; Fouad TM; Dawood S; Ueno NT; Valero V; Andreopoulou E; Alvarez RH; Woodward WA; Hortobagyi GN; Cristofanilli M; Reuben JM
Breast Cancer Res; 2015 Jan; 17(1):2. PubMed ID: 25572591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
